lopinavir has been researched along with Cytokine Release Syndrome in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battegay, M; Marzolini, C; Sendi, P; Stader, F | 1 |
| Magro, G | 1 |
| Baettig, V; Bassetti, S; Battegay, M; Egli, A; Franzeck, F; Gebhard, CE; Geenen, J; Hirsch, HH; Hollinger, A; Khanna, N; Marzolini, C; Mueller, D; Osthoff, M; Sendi, P; Stader, F; Stoeckle, M; Tschudin-Sutter, S; Weisser, M | 1 |
| Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S | 1 |
| Alharthy, A; Alshaya, R; Brindley, PG; Faqihi, F; Karakitsos, D; Kutsogiannis, DJ; Papanikolaou, J | 1 |
| Guo, F; Li, S; Liu, C; Shang, D; Taleb, SJ; Tong, M | 1 |
| Gao, C; Jin, CC; Tong, YX; Xiao, AT; Zhang, S; Zhu, L | 1 |
| Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M | 1 |
4 review(s) available for lopinavir and Cytokine Release Syndrome
| Article | Year |
|---|---|
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Anticoagulants; Antiviral Agents; Azetidines; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Disseminated Intravascular Coagulation; Drug Combinations; Heparin; Humans; Hydroxychloroquine; Inflammation; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ritonavir; SARS-CoV-2; Sulfonamides | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines | 2020 |
Traditional Chinese Medicine as Potential Therapy for COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Janus Kinase Inhibitors; Lopinavir; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Factual; Humans; Hydroxychloroquine; Immunoglobulins; Lopinavir; Pandemics; Pyrazines; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2021 |
4 other study(ies) available for lopinavir and Cytokine Release Syndrome
| Article | Year |
|---|---|
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytokine Release Syndrome; Cytokines; Humans; Lopinavir; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Ritonavir | 2022 |
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Administration Schedule; Drug Combinations; Female; Hospitals, University; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2020 |
Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report.
Topics: Adult; Antiviral Agents; Betacoronavirus; Cardiotonic Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Echocardiography; Humans; Lopinavir; Male; Pandemics; Plasma Exchange; Pneumonia, Viral; Respiration, Artificial; Respiratory Distress Syndrome; Ritonavir; SARS-CoV-2; Shock, Cardiogenic; Takotsubo Cardiomyopathy | 2020 |
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; China; Comorbidity; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Diabetes Mellitus; Drug Combinations; Female; Hospitalization; Humans; Hydroxychloroquine; Hypertension; Interferons; Lopinavir; Lymphopenia; Male; Middle Aged; Receptors, Interleukin-2; Retrospective Studies; Risk Factors; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Tumor Necrosis Factor-alpha; Virus Shedding | 2020 |